Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Perspectum
Oxford, England, United Kingdomperspectum.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Perspectum’s non-invasive MRI-based digital diagnostics have been validated in over 50 clinical trials for chronic liver disease and are commercially available. Their cT1 biomarker predicts clinical outcomes in chronic liver disease; their MRCP+ product has FDA clearance. The company continues to expand into multi-organ imaging and oncology applications with ongoing research collaborations and new grants from the FDA.
- Therapeutic areas
- GastroenterologyMetabolic DisordersOncologyInfectious Diseases
- Modalities
- DeviceSoftwareImaging biomarker
- Industry
- Medical Imaging
02
Partnerships
University of Oxford
Beyond the preview
Go deeper on Perspectum.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Perspectum.